


Applicant : Or et al.  
 Serial Number : 09/976, 219  
 Filed : October 12, 2001  
 Page : 10

# Amendments to the claims:


1. (Original) A cyclosporin analog of formula I or a pro-drug or a pharmaceutically acceptable salt thereof:



(I)


wherein

- (i) A is of the formula:



(A1)

or



(A2)

wherein:

- X is absent, -C1-C6 alkyl-, or -C3-C6 cycloalkyl-;
- Y is selected from the group consisting of:  
 aryl, substituted aryl, heteroaryl, and substituted heteroaryl;
- (ii) - B is - $\alpha$ Abu-, -Val-, -Thr- or -Nva-; and
- (iii) U is -(D)Ala-, -(D)Ser-, -[O-(2-hydroxyethyl)(D)Ser]-, -[O-(acyl)(D)Ser]- or -[O-(2-acyloxyethyl)(D)Ser]-.

2. (Original) A cyclosporin analog according to Claim 1 or a pro-drug or a pharmaceutically acceptable salt thereof, wherein in formula I, B is

Applicant : Or et al.  
 Serial Number : 09/976, 219  
 Filed : October 12, 2001  
 Page : 11

- $\alpha$ Abu-, and U is -(D)Ala-.

3. (Original) A cyclosporin analog according to Claim 1 or a pro-drug or a pharmaceutically acceptable salt thereof, wherein in formula I:

(i) A is of the formula A1 or A2, wherein:

X is absent; and

Y is selected from the group consisting of:

aryl, substituted aryl, heteroaryl, and substituted heteroaryl;

(ii) B is - $\alpha$ Abu-; and

(iii) U is -(D)Ala-.

4. (Currently Amended) A cyclosporin analog according to Claim 1 or a pro-drug or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

Compound of formula (I), where A=A1, X is absent and Y = (2'-Me)Ph; B is - $\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-F)Ph; B is - $\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-CF<sub>3</sub>)Ph; B is - $\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2'-Br)Ph; B is - $\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2'-Cl)Ph; B is - $\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2'-OMe)Ph; B is - $\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (3'-Cl)Ph; B is - $\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-Cl)Ph; B is - $\alpha$ Abu-; and U is -(D)Ala-;

Applicant : Or et al.  
Serial Number : 09/976, 219  
Filed : October 12, 2001  
Page : 12

Compound of formula (I), where A=A1, X is absent and Y = (3'-Br)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-Br)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (3'-COOCH<sub>3</sub>)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-COOCH<sub>3</sub>)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2'-Naphthalene); B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-t-butyl)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (pentafluoro)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-AcO-)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-OCH<sub>3</sub>)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (3', 4'-OMe<sub>2</sub>)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2',5'-Me<sub>2</sub>)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = Pyridine; B is  $-\alpha$ Abu; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = Pyrrole; B is  $-\alpha$ Abu; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (N-methyl) Pyrrole; B is  $-\alpha$ Abu; and U is -(D)Ala-;

Applicant : Or et al.  
 Serial Number : 09/976, 219  
 Filed : October 12, 2001  
 Page : 13

Compound of formula (I), where A=A1, X is absent and Y = Thiophene; B is  $-\alpha$ Abu; and U is  $-(D)Ala-$ ;

Compound of formula (I), where A=A1, X is absent and Y = Oxazole; B is  $-\alpha$ Abu; and U is  $-(D)Ala-$ ;

Compound of formula (I), where A=A2, X is absent and Y = (2'-Me)Ph; B is  $-\alpha$ Abu; and U is  $-(D)Ala-$ ;

Compound of formula (I), where A=A1, X is absent and Y = (S)Ph; B is  $-\alpha$ Abu; and U is  $-(D)Ala-$ ;

Compound of formula (I), where A=A1, X is absent and Y = (SO)Ph; B is  $-\alpha$ Abu; and U is  $-(D)Ala-$ ; and


Compound of formula (I), where A=A1, X is absent and Y = (SO<sub>2</sub>)Ph; B is  $-\alpha$ Abu; and U is  $-(D)Ala-$ .

Claims 5-10 (Withdrawn)

11. (Original) A pharmaceutical composition, said composition comprising at least one cyclosporin analog of formula I as claimed in Claim 1, said cyclosporin analog being present alone or in combination with a pharmaceutically acceptable carrier or excipient.

Claims 12-14 (Withdrawn)


15. (New) A cyclosporin analog of formula I or a pro-drug or a pharmaceutically acceptable salt thereof:



(I)

wherein

or



wherein:

Y is selected from the group consisting of:

(a) aryl substituted with one or more substituents independently selected from: CN, C<sub>1</sub>-C<sub>3</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub>-alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>3</sub>-C<sub>6</sub>-alkoxy substituted with aryl, haloalkyl, thioalkoxy, amino, alkylamino, mercapto, nitro, carboxaldehyde, carboxy, alkoxycarbonyl, or carboxamide;

(b) heteroaryl; or

(c) substituted heteroaryl;

(ii) B is - $\alpha$ Abu-, -Val-, -Thr- or -Nva-; and

(iii) U is -(D)Ala-, -(D)Ser-, -[O-(2-hydroxyethyl)(D)Ser]-, -[O-(acyl)(D)Ser]- or -[O-(2-acyloxyethyl)(D)Ser]-.

16. (New) A cyclosporin analog of claim 15 defined by formula I, wherein X is absent and Y is phenyl substituted at the ortho position with a substituent independently selected from: CN, C<sub>1</sub>-C<sub>3</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub>-alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>3</sub>-C<sub>6</sub>-alkoxy substituted with aryl, haloalkyl, thioalkoxy, amino, alkylamino, mercapto, nitro, carboxaldehyde, carboxy, alkoxycarbonyl, or carboxamide.

Applicant : Or et al.  
Serial Number : 09/976, 219  
Filed : October 12, 2001  
Page : 15

17. (New) A cyclosporin analog according to claim 15 or a pro-drug or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

Compound of formula (I), where A=A1, X is absent and Y = (2'-Me)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-CF<sub>3</sub>)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2'-OMe)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (3'-COOCH<sub>3</sub>)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-COOCH<sub>3</sub>)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2'-Naphthalene); B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-t-butyl)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-AcO-)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (4'-OCH<sub>3</sub>)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (3', 4'-OMe<sub>2</sub>)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = (2',5'-Me<sub>2</sub>)Ph; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Compound of formula (I), where A=A1, X is absent and Y = Pyridine; B is  $-\alpha$ Abu-; and U is -(D)Ala-;

Applicant : Or et al.  
Serial Number : 09/976, 219  
Filed : October 12, 2001  
Page : 16

Compound of formula (I), where A=A1, X is absent and Y = Pyrrole; B is  $-\alpha$ Abu; and U is  $-(D)Ala-$ ;

Compound of formula (I), where A=A1, X is absent and Y = (N-methyl) Pyrrole; B is  $-\alpha$ Abu; and U is  $-(D)Ala-$ ;

Compound of formula (I), where A=A1, X is absent and Y = Thiophene; B is  $-\alpha$ Abu; and U is  $-(D)Ala-$ ;

Compound of formula (I), where A=A1, X is absent and Y = Oxazole; B is  $-\alpha$ Abu; and U is  $-(D)Ala-$ ;

Compound of formula (I), where A=A2, X is absent and Y = (2'-Me)Ph; B is  $-\alpha$ Abu; and U is  $-(D)Ala-$ ;

Compound of formula (I), where A=A1, X is absent and Y = (S)Ph; B is  $-\alpha$ Abu; and U is  $-(D)Ala-$ ;

Compound of formula (I), where A=A1, X is absent and Y = (SO)Ph; B is  $-\alpha$ Abu; and U is  $-(D)Ala-$ ; and

Compound of formula (I), where A=A1, X is absent and Y = (SO<sub>2</sub>)Ph; B is  $-\alpha$ Abu; and U is  $-(D)Ala-$ .

18. (New) A cyclosporin analog of formula (I), where A=A1, X is absent and Y = (2'-Me)Ph; B is  $-\alpha$ Abu-; and U is  $-(D)Ala-$ .
19. (New) A pharmaceutical composition, said composition comprising at least one cyclosporin analog of formula I as claimed in Claim 15, said cyclosporin analog being present alone or in combination with a pharmaceutically acceptable carrier or excipient.